NRx Pharmaceuticals, Inc.
NRXP
$2.75
$0.124.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.16% | 5.96% | 16.66% | 43.48% | 36.49% |
| Total Depreciation and Amortization | -40.00% | -20.00% | 0.00% | 0.00% | 25.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,151.93% | 1,045.69% | 362.15% | -85.58% | -60.77% |
| Change in Net Operating Assets | -106.52% | -39.40% | 2.46% | 128.58% | 77.10% |
| Cash from Operations | 14.85% | 45.70% | 50.88% | 56.20% | 50.89% |
| Capital Expenditure | -- | -- | -- | 133.33% | 83.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 133.33% | 83.33% |
| Total Debt Issued | 7,881.53% | 1,180.91% | 650.69% | -71.33% | -98.55% |
| Total Debt Repaid | -11.67% | -8.89% | -112.52% | -119.88% | -6,678.89% |
| Issuance of Common Stock | -38.97% | -18.59% | -27.22% | -28.13% | -30.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,306.31% | 262.26% | 20.71% | -74.34% | -95.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.74% | 127.85% | 79.61% | 22.37% | -36.45% |